openPR Logo
Press release

Investigation for NASDAQ: OSMT Investors announced over potential Wrongdoing at Osmotica Pharmaceuticals plc

01-14-2020 09:07 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Osmotica Pharmaceuticals plc (NASDAQ: OSMT) shares over potential wrongdoing.

An investigation on behalf of investors in Osmotica Pharmaceuticals plc (NASDAQ: OSMT) shares over potential wrongdoing.

An investigation on behalf of investors in shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) was announced over potential breaches of fiduciary duties by certain officers and directors at Osmotica Pharmaceuticals plc.

Investors who purchased shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Osmotica Pharmaceuticals plc (NASDAQ: OSMT officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Bridgewater, NJ based Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. Osmotica Pharmaceuticals plc reported that its annual Total Revenue rose from $245.74 million in 2017 to $263.7 million in 2018 and that its Net Loss increased from $41.14 million in 2017 to $109.39 million in 2018.

On March 27, 2019, after the markets closed, Osmotica Pharmaceuticals plc announced preliminary results for a second Phase 3 clinical trial of arbaclofen extended-release tablets that failed to beat placebo as measured by the Clinical Global Impression of Change.

Those who purchased shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for NASDAQ: OSMT Investors announced over potential Wrongdoing at Osmotica Pharmaceuticals plc here

News-ID: 1896245 • Views: 220

More Releases from Shareholders Foundation

Lawsuit filed for Investors in shares of Green Dot Corporation (NYSE: GDOT)
An investor, who purchased shares of Green Dot Corporation (NYSE: GDOT), filed a lawsuit over alleged Securities Laws violations by Green Dot Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Green Dot Corporation (NYSE: GDOT) have certain options and for certain investors are short and strict deadlines running. Deadline: February 17, 2020. NYSE: GDOT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or
Investigation for Long-Term Investors in shares of Nektar Therapeutics (NASDAQ: …
An investigation was annpounced concerning potential breaches of fiduciary duties by certain directors and officers of Nektar Therapeutics. Investors who are current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: NKTR stocks follows a lawsuit filed against Nektar Therapeutics over
Deadline coming up on Jan. 20th in Lawsuit filed for Investors in shares of Cano …
A deadline is coming up on January 20, 2020 in the lawsuit filed for certain investors of Canopy Growth Corporation (NYSE: CGC) over alleged securities laws violations by Canopy Growth Corporation. Investors who purchased shares of Canopy Growth Corporation (NYSE: CGC) have certain options and there are strict and short deadlines running. Deadline: January 20, 2020. NYSE: CGC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation for Investors in NYSE: LTHM shares announced over potential Securi …
Livent Corporation is under investigation concerning potential securities laws in connection with certain financial statements. Investors who purchased shares of Livent Corporation (NYSE: LTHM), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Livent Corporation (NYSE: LTHM) concerning whether a series of statements by Livent Corporation

All 5 Releases


More Releases for Osmotica

Parkinson’s Disease Market Insight, Segment Forecast With Teva Pharmaceutical, …
The parkinson’s disease market report serves with all-inclusive, highly-effective, and thoroughly analyzed information in a well-organized manner, based on actual facts, about the Market. The whole information from the scratch to the financial and management level of the established industries associated with the Market at the global level is initially acquired by the dedicated team. The gathered data in this parkinson’s disease report involves the information about the industry’s establishment,
Spasticity Therapeutics- Pipeline Analysis 2018 | Top Player are Osmotica Pharma …
Spasticity is a condition in which certain muscles are continuously contracted. The constant muscle contraction causes stiffness or tightness of the muscles and can interfere with normal movement, speech and gait in a patient. Download the sample report @ https://www.pharmaproff.com/request-sample/1088 Spasticity is usually caused by damage to the portion of the brain or spinal cord that controls voluntary movement. This damage causes a change in the balance of signals between the nervous
Global 3D Printed Drugs Market Demand, Scope, Future Expectations, Market overvi …
A Comprehensive research study conducted by KD Market Insights on " 3D Printed Drugs Market - By Application (Neurology, Orthopedic, Hearing & Audibility Aid, Dental, Medical Implants, Others) and Global Region Market Size, Share, Opportunity & Forecast 2018-2023” report offers extensive and highly detailed historical, current and future market trends in the Global and regional/market. The 3D Printed Drugs Market report includes market size, growth drivers, barriers, opportunities, trends and
3D Printed Drugs Market 2018 Analysis by Segment, Top Leading Companies are (Apr …
The Global 3D Printed Drugs Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Growing usuage of 3D printing and increasing adoption of personalized drugs are the potential factor for the growth of this market. Growth in 3D printed drugs market is driven by the factors like rising health related and growing population across the globe. Increase in healthcare investment
3D Printed Drugs Market Will Multiply At An Impressive CAGR By 2024 & Top Key Pl …
The 3D printed drugs market has been segmented by end users into hospitals, clinics and research laboratories, all of which are anticipated to drive the production of 3D printed drugs in pharmaceutical manufacturing companies. Drugs or Pills made by powder-liquid three dimensional techniques are comparatively more soluble than other drugs or pills. Additionally, 3D printed drugs are able to dissolve insoluble compounds such as silver chloride very easily. Factors such
Global Drug Delivery Technology Market Size, Status and Forecast 2022 - GSK, Bay …
ResearchMoz added Latest Research Report titled " Global Drug Delivery Technology Market Size, Status and Forecast 2022 " to it's Large Report database. This report studies the global Drug Delivery Technology market, analyzes and researches the Drug Delivery Technology development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Johnson & Johnson F. Hoffman-La Roche Merck & Co. Bayer Pfizer Novartis 3M Company Becton,